Cargando…

1828. Dalbavancin Utilization and Associated Clinical Outcomes: A Case-Series

BACKGROUND: Dalbavancin is an intravenous (IV) long acting lipoglycopeptide approved for use in acute bacterial skin and skin structure infections (ABSSSI). However, given the prolonged half-life, there is interest in using this agent as an alternative therapy for patients unable or unwilling to com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greckel, Meagan N, Footer, Brent, Christensen, Alyssa, Tallman, Gregory B, Edwards, Lea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752586/ http://dx.doi.org/10.1093/ofid/ofac492.1458

Ejemplares similares

1091. Validation of an Allometrically Scaled Body Weight Equation to Predict Vancomycin Clearance and Guide 24-Hour Vancomycin AUC Dosing in Obese Patients
por: Footer, Brent, et al.
Publicado: (2021)

Impact of a Laboratory-Developed Phenotypic Rapid Susceptibility Test Directly From Positive Blood Cultures on Time to Narrowest Effective Therapy in Patients With Gram-Negative Bacteremia: A Prospective Randomized Trial
por: Christensen, Alyssa B, et al.
Publicado: (2022)

1828. The Stratification of HIV Viral Suppression Rates and Related Health Outcomes of UNMC HIV Clinic Patients by Local Zip Code in Omaha, NE
por: Carter, Mark, et al.
Publicado: (2023)

1660. Dalbavancin Utilization Registry Investigating Value and Effectiveness (DRIVE): Outcomes Report on Real-World Use
por: Jones, Bruce M, et al.
Publicado: (2022)

1056. Safety and Tolerability of Dalbavancin in Vancomycin Allergic Patients – A Case Series
por: Freeman, Kennedy J, et al.
Publicado: (2021)

314. A Retrospective Review of Dalbavancin Utilization at an Academic Medical Center
por: Napoli, Emma, et al.
Publicado: (2020)

438. Dalbavancin Clinical Experience at an NCI Designated Cancer Center
por: McDaneld, Patrick, et al.
Publicado: (2019)

London in 1828
Publicado: (1889)

Surgery in 1828
por: Edington, G. H.
Publicado: (1928)

1828. Interrupted Time Series Analysis of a Population-Level Academic Detailing Intervention on UTIs in British Columbia’s Nursing Homes
por: Sharma, Prateek, et al.
Publicado: (2018)

2902. Dalbavancin Use in Bone and Joint Infections
por: Sanikommu, Srivani, et al.
Publicado: (2023)

2764. Experience with dalbavancin in a pediatric hospital
por: Leon, Maria Deza, et al.
Publicado: (2023)

1178. The Dalba Diary: A Retrospective Review of Dalbavancin Use, Clinical Outcomes, and Treatment Adherence Challenges at an Academic Medical Center
por: Black, Cassandra E, et al.
Publicado: (2023)

613. Clinical Outcomes Following Dalbavancin Administration during Outpatient Parenteral Antimicrobial Therapy
por: Tuan, Jessica, et al.
Publicado: (2021)

1828. Bedaquiline Resistance in Mycobacterium intracellulare Is Mediated by the Transcriptional Repressor MmpT5
por: Alexander, David, et al.
Publicado: (2019)

Gibraltar Epidemic of 1828
por: Fraser, H.
Publicado: (1831)

1004. Dalbavancin Use and Associated Cost-Savings: An Update
por: Streifel, Amber C, et al.
Publicado: (2022)

2362. Emergency Department Resource Utilization After Implementation of a Dalbavancin Pathway for Skin and Soft-Tissue Infections
por: Heil, Emily, et al.
Publicado: (2018)

2380. Healthcare Resource Utilization for High-Risk Patients Treated With Dalbavancin in Physician Office Infusion Centers (POICs)
por: Luu, Quyen, et al.
Publicado: (2018)

Use of dalbavancin in infective endocarditis: a case series
por: Guleri, Achyut, et al.
Publicado: (2021)

599. Dalbavancin Utilization in Rural Healthcare Setting: A Single Center Three Years’ Experience
por: AlSalman, Ahmad, et al.
Publicado: (2020)

1365. Clinical and Financial Implication of Dalbavancin Utilization on Length of Stay Avoidance in Acute Bacterial Skin and Skin Structure Infection
por: Kim, Sonia S, et al.
Publicado: (2021)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

1028. Dalbavancin Use in Complicated Infections and-associated Cost-Savings
por: Streifel, Amber C, et al.
Publicado: (2019)

225. Dalbavancin Usage in Patients Who Inject Drugs (PWID)
por: Patel, Kaya, et al.
Publicado: (2023)

The washington community 1800-1828 /

2765. Dalbavancin for challenging left ventricular assist device driveline infections
por: Doligalski, Christina, et al.
Publicado: (2023)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

122. Dalbavancin Use in Patients with Substance Use Disorders
por: Streifel, Amber C, et al.
Publicado: (2020)

614. Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2021)

279. Dalbavancin for Bloodstream Infections and Endocarditis: Real-World Outcomes From the DRIVE Registry
por: Gonzalez, Pedro, et al.
Publicado: (2020)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

108. Evaluation of the Impact of Dalbavancin Usage on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital
por: Wei, Wenjing, et al.
Publicado: (2021)

1730. Real-World Use Of Dalbavancin In A US Tertiary Referral Center
por: Bhugra, Mudita, et al.
Publicado: (2022)

1286. Evaluating Dalbavancin Suppression Therapy in Patients at High Risk for Recurrent Infections
por: Shaw, Michael, et al.
Publicado: (2023)

Andrew Taylor Still, 1828–1917
por: Cooter, Roger
Publicado: (1992)

The history of medicine in Finland 1828–1918
Publicado: (1977)

John Langdon Down (1828 – 1896)
por: Van Robays, J
Publicado: (2016)

Remarks on the Origin of the Gibraltar Fever of 1828
por: Guyon, M.
Publicado: (1831)

Statistics of the Dental Art in Paris in 1828
por: Maury, F., et al.
Publicado: (1841)

Cannot write session to /tmp/vufind_sessions/sess_clgo1ppj3ic1269fvm1v76ruu6